Literature DB >> 17235610

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.

Nikolas Klein1, Julia Sacher, Thomas Geiss-Granadia, Nilufar Mossaheb, Trawat Attarbaschi, Rupert Lanzenberger, Christoph Spindelegger, Alexander Holik, Susanne Asenbaum, Robert Dudczak, Johannes Tauscher, Siegfried Kasper.   

Abstract

OBJECTIVES: Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [(123)I]ADAM and single photon emission computed tomography (SPECT).
METHODS: Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake.
RESULTS: At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean+/-SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain.
CONCLUSION: The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235610     DOI: 10.1007/s00213-006-0666-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand.

Authors:  S Oya; S R Choi; C Hou; M Mu; M P Kung; P D Acton; M Siciliano; H F Kung
Journal:  Nucl Med Biol       Date:  2000-04       Impact factor: 2.408

2.  Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.

Authors:  Akihiro Takano; Tetsuya Suhara; Tetsuya Ichimiya; Fumihiko Yasuno; Kazutoshi Suzuki
Journal:  J Clin Psychopharmacol       Date:  2006-04       Impact factor: 3.153

3.  Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.

Authors:  Nicholas Moore; Hélène Verdoux; Bruno Fantino
Journal:  Int Clin Psychopharmacol       Date:  2005-05       Impact factor: 1.659

4.  The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.

Authors:  B Søgaard; H Mengel; N Rao; F Larsen
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

Review 5.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.

Authors:  Michael Bauer; Peter C Whybrow; Jules Angst; Marcio Versiani; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2002-01       Impact factor: 4.132

6.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

7.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

Review 8.  Escitalopram: a review of its use in the management of major depressive disorder.

Authors:  David Murdoch; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Unique mechanism of action for escitalopram: does it hold the promise?

Authors:  Siegfried Kasper
Journal:  Int J Psychiatry Clin Pract       Date:  2004       Impact factor: 1.812

10.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Authors:  Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

View more
  15 in total

1.  A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.

Authors:  Marina Sagud; Matea Nikolac Perkovic; Bjanka Vuksan-Cusa; Anja Maravic; Dubravka Svob Strac; Alma Mihaljevic Peles; Maja Zivkovic; Zorana Kusevic; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2016-06-29       Impact factor: 4.530

2.  Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.

Authors:  Barbara Drueke; Julia Baetz; Maren Boecker; Olaf Moeller; Christoph Hiemke; Gerd Gründer; Siegfried Gauggel
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 4.  Escitalopram: a review of its use in the management of major depressive disorder in adults.

Authors:  Karly P Garnock-Jones; Paul L McCormack
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

5.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

6.  The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men.

Authors:  Elsmarieke van de Giessen; Jan Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

7.  Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers.

Authors:  Alan N Simmons; Estibaliz Arce; Kathryn L Lovero; Murray B Stein; Martin P Paulus
Journal:  Int J Neuropsychopharmacol       Date:  2009-06-23       Impact factor: 5.176

8.  Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.

Authors:  M Kreilgaard; D G Smith; L T Brennum; C Sánchez
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

Review 9.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

10.  Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Authors:  Eiji Kirino
Journal:  Patient Prefer Adherence       Date:  2012-12-04       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.